Biomark Diagnostics Inc. (FRA:20B)
Germany · Delayed Price · Currency is EUR | Market Cap | 29.39M +38.4% |
| Revenue (ttm) | 17.14K -82.1% |
| Net Income | -878.62K |
| EPS | -0.01 |
| Shares Out | 106.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.2820 |
| Previous Close | 0.2760 |
| Day's Range | 0.2760 - 0.2820 |
| 52-Week Range | 0.1530 - 0.4200 |
| Beta | -0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 27, 2026 |
About Biomark Diagnostics
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada. [Read more]
Financial Performance
In fiscal year 2026, Biomark Diagnostics's revenue was 59,787, a decrease of -61.23% compared to the previous year's 154,216. Losses were -1.48 million, -23.35% less than in 2025.
Financial numbers in CAD Financial StatementsNews
BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
Five peer-reviewed studies published in nine months independently confirm high accuracy, robust panel optimization, and commercial viability of BioMark's blood-based assay. Vancouver, British Columbia...
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
Anchored in the 2026 global campaign's core mission of early detection, equitable access to screening, and compassionate patient support, BioMark advances its multi-marker liquid biopsy to ensure no p...
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
BioMark prepares to launch its breakthrough liquid biopsy powered by a newly patented algorithm validated in over 15,000 samples across Quebec, France, and Germany. Vancouver, British Columbia--(Newsf...
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
New patent expands globally protected IP estate beyond blood into alternative biofluids, positioning the Company's clinical mass spectrometry platform against traditional genomic liquid biopsies. Vanc...
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
BioMark Comprehensive Metabolomics Assay Selected as Top Canadian Innovation for the CTS Beaver Den Innovation Award Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark Diagnostic...
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data Enrichment for Enhanced Diagnostic Capabilities Vancouver, British Columbia--(Newsfile Corp. - Ja...
BioMark: 2025 Achievements & 2026 Vision
Celebrating A Year of Extraordinary Achievement Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Com...
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
Expanding U.S. market access with an experienced technology investor and AI-driven growth strategist Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: ...
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026 Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE...
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform Vancouver, British Columbia--(Newsfile Corp. - December ...
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Next-generation metabolomics and AI technology supports the 2026 - 2035 Pan-Canadian Lung Cancer Action Plan's call to expand equitable access to life-saving early diagnosis Vancouver, British Columbi...
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
Extensive Validation of BioMark's Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network. Vancouve...
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets. Vancouver, British Columbia--(Newsfile Corp....
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone Markets Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE:...
BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark Diagno...
BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests f...
BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology
Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. Vancouver, British Columbia--(Newsfile Corp. - ...
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test
Study Published in a special issue of International Journal of Molecular Sciences Confirms Test's Ability to Distinguish Early Lung Cancer from Other Non-Cancerous Lung Diseases Vancouver, British Col...
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMa...
BioMark Announces the Final Closing of Oversubscribed Private Placement
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early canc...
BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025
BioMark is pioneering liquid biopsy solutions for challenging conditions and championing equity in diagnosis Vancouver, British Columbia--(Newsfile Corp. - February 28, 2025) - BioMark Diagnostics Inc...
BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction
BioMark Expands Its Liquid Biopsy Platform Receptor Status for Breast Cancer Vancouver, British Columbia--(Newsfile Corp. - December 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pin...
BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection
BioMark Strengthens Liquid Biopsy Platform for Breast Cancer Detection Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF...
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN
BioMark's Liquid Biopsy Technology Offers Promise for NEN Diagnosis Vancouver, British Columbia--(Newsfile Corp. - September 24, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF...
BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection
Largest Clinical Study Validating a Metabolite-based Assay for Lung Cancer Screening Vancouver, British Columbia--(Newsfile Corp. - September 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B)...